NCT04788953View on ClinicalTrials.gov

Clinical Trial of Solriamfetol for Excessive Sleepiness Related to Shift Work Disorder

PHASE4TerminatedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

July 21, 2021

Primary Completion Date

April 6, 2024

Study Completion Date

April 19, 2024

Conditions
Excessive SleepinessShift-work Disorder
Interventions
DRUG

Solriamfetol Oral Tablet

The administered drug is SUNOSI (solriamfetol) tablets for oral use. Initial U.S. Approval: 2019

DRUG

Placebo

Control subjects will receive placebo tablets for oral use.

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston

Sponsors

Collaborators (1)

Axsome Therapeutics, Inc.
All Listed Sponsors
collaborator

Axsome Therapeutics, Inc.

INDUSTRY

lead

Charles A. Czeisler, PhD, MD

OTHER